By staff writers

November 7, 2019 -- Grifols announced it is offering a genetic cheek swab test that screens for alpha-1 antitrypsin (AAT) deficiency in patients with chronic obstructive pulmonary disease (COPD) for free -- including testing and results.

An estimated 100,000 people in the U.S. have AAT deficiency, the company said. Grifols' AlphaID tests for 14 genetic mutations associated with AAT deficiency, which typically remains undiagnosed even though screening is simple, Grifols said. It takes seconds to perform the test, and results are available within a week.

The company is also offering at no charge to consumers the AlphaID Confirm finger-stick blood test, which can be used to ascertain genotype and AAT level and confirm the diagnosis.

The AlphaID cheek swab test
The AlphaID cheek swab test. Image courtesy of Grifols.
Pathology documents lung damage from vaping
A small study of lung biopsy specimens clearly demonstrates the damage of vaping to the lungs, particularly vaping tetrahydrocannabinol, pathologists...
MicroRNAs predict problems in pneumonia patients
Certain small molecules involved in lung and systemic inflammatory processes show promise as affordable blood-based biomarkers for pneumonia patients...
C-reactive protein tests help curb antibiotic use in acute COPD
Point-of-care testing for the inflammatory marker C-reactive protein helped reduce the use of antibiotics for acute cases of chronic obstructive pulmonary...

Copyright © 2019

Last Updated np 11/7/2019 5:06:03 PM

Register below for our weekly Letter from the Editor to receive the latest Clinical Lab news and insights.